A patient is found unresponsive. The history is incomplete. The
patient is apneic and pulseless. CPR begins, ventilation is established,
and the monitor shows organized electrical activity without a pulse:
PEA.
Then someone identifies evidence suggesting opioid exposure.
The question is immediate: if the patient is already in
cardiac arrest, does naloxone still matter?
A 2026 Resuscitation study adds an important piece of
evidence. In a national retrospective cohort, naloxone administration
was associated with improved survival to hospital discharge among
patients whose initial rhythm was PEA. The same outcome association was
not found for shockable rhythms or asystole.
That is interesting evidence. It is not proof that naloxone causes
survival in PEA, and it does not justify allowing naloxone to delay CPR,
ventilation, rhythm management, defibrillation when indicated, standard
ACLS care, or treatment of reversible causes.
LSE Bottom Line: Current 2025 AHA guidance says an
opioid antagonist such as naloxone may be reasonable during suspected
opioid-associated cardiac arrest if its administration does not
interfere with standard resuscitation, including high-quality
compression-ventilation CPR.
Table of Contents
- Why this question matters
- What the 2026 study found
- What it did not prove
- Why PEA is biologically interesting
- Respiratory arrest versus cardiac arrest
- What current AHA guidance says
- Naloxone versus ventilation is the wrong argument
- Why observational arrest research is difficult
- Recognizing opioid-associated OHCA
- PEA is not a diagnosis
- Polysubstance overdose
- Operational application
- Quality improvement
- Training scenario
- Common misconceptions
- Does this change practice?
- FAQ
- Key takeaways
- References
Why This Question Matters
Opioid-associated OHCA often begins as a respiratory emergency.
Opioids depress central respiratory drive. Respiratory rate and tidal
volume fall, carbon dioxide rises, oxygenation deteriorates, and
untreated respiratory depression can progress to respiratory arrest,
severe hypoxemia, bradycardia, cardiovascular collapse, PEA, and
eventually asystole.
Naloxone has its clearest role before circulation is lost. In a
patient with suspected opioid poisoning who has respiratory arrest but a
definite pulse, ventilation immediately supports gas exchange while
naloxone can antagonize the opioid effect.
Once the patient becomes pulseless, however, the physiology changes
dramatically. There is no effective spontaneous circulation. Coronary
and cerebral perfusion depend on CPR-generated blood flow. Ventilation
is needed to address gas exchange. Shockable rhythms require
defibrillation. Reversible causes require active treatment.
This is why naloxone after cardiac arrest begins cannot simply be
assumed to behave as it does in a perfusing overdose patient.
What the 2026 Study Found
Niederberger and colleagues used 2019-2020 data from the ESO Data
Collaborative in a retrospective cohort study of EMS-treated OHCA. After
inclusion criteria were applied, 40,333 cases were analyzed. Naloxone
was administered in 7,567 cases, or 18.8%.
Cases were classified by presenting rhythm: shockable rhythm, PEA, or
asystole. Outcomes were prehospital ROSC and survival to hospital
discharge.
Before matching, overall prehospital ROSC was 21.5% and survival to
discharge was 9.0%.
After propensity-score matching, the PEA subgroup receiving naloxone
had similar prehospital ROSC, OR 1.09 with a 95% CI of 0.90-1.31, but
higher survival to hospital discharge, OR 1.46 with a 95% CI of
1.11-1.92.
Naloxone was not associated with improved outcomes in the
shockable-rhythm or asystole groups.
The survival signal is noteworthy, but it also raises questions. A
survival association without a statistically significant ROSC
association does not provide a simple causal story. It reinforces the
need for prospective research.
What the Study Did Not Prove
This was not a randomized trial. EMS clinicians decided who received
naloxone.
Patients receiving naloxone differed from patients who did not. The
naloxone group was younger, for example, and clinicians were likely
influenced by history, scene clues, patient characteristics, rhythm, and
suspicion of overdose.
Propensity-score matching can reduce measured imbalance, but it
cannot remove every unmeasured confounder.
The authors explicitly identify selection bias, unmeasured
confounding, and resuscitation-time bias as limitations. They state that
causality cannot be established.
The correct conclusion is therefore:
Naloxone was associated with improved survival to hospital
discharge in matched PEA cases.
It is not:
Naloxone has been proven to improve survival in
PEA.
That difference is central to evidence-based EMS education.
Why PEA Is Biologically
Interesting
A simplified progression of severe opioid poisoning can be
conceptualized as:
opioid effect → respiratory depression → respiratory arrest →
hypoxemia → bradycardia → PEA → asystole
Real patients are more complicated, but this pathway provides a
biologically plausible reason that opioid-associated arrests may be
represented among nonshockable rhythms.
PEA, however, is not an etiology. It is an electrical
description.
Massive hemorrhage, pulmonary embolism, tension pneumothorax,
tamponade, hypoxia, severe metabolic derangement, toxicologic
emergencies, and many other processes can produce PEA.
Rhythm may contribute to suspicion. It cannot diagnose opioid
poisoning.
Respiratory Arrest
Versus Cardiac Arrest
The distinction between respiratory arrest with a pulse and cardiac
arrest is critical.
For suspected opioid overdose with respiratory depression or
respiratory arrest and a definite pulse, current AHA guidance emphasizes
airway support and breaths or bag-mask ventilation. For trained
rescuers, an opioid antagonist such as naloxone should be administered
in respiratory arrest with a definite pulse.
Ventilation should not wait for the medication to work. Intranasal or
intramuscular naloxone may require time. Polysubstance exposure may
limit the apparent response. Aspiration or another disease process may
coexist.
Once the pulse is lost, the resuscitation hierarchy changes.
High-quality CPR, ventilation, rhythm assessment, defibrillation when
indicated, standard arrest medications, and reversible-cause treatment
take priority.
Naloxone becomes a possible adjunct when opioid-associated arrest is
suspected.
What Current AHA Guidance
Says
The 2025 AHA Guidelines provide a useful framework.
For suspected opioid overdose with respiratory arrest and a definite
pulse, trained rescuers should provide breaths or bag-mask ventilation
and administer an opioid antagonist.
For suspected opioid-associated cardiac arrest, opioid antagonist
administration may be reasonable, provided it does not
interfere with standard resuscitation, including high-quality
compression-ventilation CPR.
The adult cardiac-arrest recommendation is Class 2b with
nonrandomized evidence.
The AHA also emphasizes that no clinical trials have established the
role of opioid antagonists during human cardiac arrest. Observational
evidence is conflicting and susceptible to confounding by
indication.
The 2026 study therefore adds evidence to an already recognized
uncertainty. It does not replace the guideline framework.
Naloxone
Versus Ventilation Is the Wrong Argument
The practical question is not “naloxone or ventilation?”
In respiratory arrest with a pulse, the patient may need both.
Ventilation immediately addresses gas exchange. Naloxone addresses
opioid receptor activity.
In cardiac arrest, compression-ventilation CPR is foundational.
Naloxone can be incorporated as a parallel task when opioid toxicity is
plausible and local protocol permits.
A task-saturated arrest scene makes this operational distinction
important. Someone has to locate and administer the medication. If that
process causes a compression pause, delays ventilation, distracts from
rhythm analysis, delays defibrillation, or prevents treatment of a more
likely reversible cause, the resuscitation has lost something more
certain in pursuit of something less certain.
The phrase “provided it does not interfere with standard
resuscitation” should therefore be treated as an operational
requirement.
Why
Observational Arrest Research Is Difficult
Confounding by indication
Clinicians choose treatments based on what they see. A younger
patient with PEA and strong overdose clues may be more likely to receive
naloxone and may also differ prognostically from an older patient with
advanced cardiovascular disease.
Resuscitation-time bias
Treatments administered later in an arrest can become associated with
poor outcomes because rapid ROSC prevents some patients from ever
receiving them. Timing can distort observational associations.
Misclassification
Opioid-associated OHCA can be difficult to identify. Scene clues and
witness reports are incomplete. Toxicology is usually unavailable to
EMS. Multiple substances may be involved.
Missing clinical variables
Large databases offer scale but cannot perfectly capture CPR quality,
ventilation quality, exact timing, no-flow interval, specific substance,
dose, post-arrest hospital care, and every other factor influencing
survival.
These limitations do not make the research useless. They determine
how strongly its conclusions should be stated.
Could Naloxone Still
Matter During Arrest?
A biologic effect during arrest is possible. If opioid receptor
activity contributed to the arrest, antagonism could theoretically
matter if sufficient medication reaches receptor sites during CPR.
PEA may also represent a different physiologic stage from prolonged
asystole in some opioid-associated arrests.
But unanswered questions remain:
- Does naloxone directly improve resuscitation physiology during
opioid-associated PEA? - Does timing matter?
- Does IV or IO administration differ from intranasal administration
during arrest? - Are certain opioids or co-ingestants associated with different
responses? - Is the observed survival difference partly a marker of a younger,
more reversible arrest population? - Why was improved survival observed without a statistically
significant improvement in prehospital ROSC?
A prospective randomized trial is needed to address causality.
Recognizing
Opioid-Associated OHCA
Potential clues include witness reports, known opioid use, preceding
respiratory depression, a witnessed overdose-to-arrest progression,
prior naloxone administration, scene context, and an otherwise
unexplained nonshockable arrest in a compatible clinical setting.
No single clue is definitive.
Pupillary findings should be interpreted cautiously because hypoxia,
medications, neurologic injury, lighting, and other factors can alter
pupil appearance.
The goal is not to label every PEA arrest an overdose. It is to keep
poisoning on the differential when the context supports it.
PEA Is Not a Diagnosis
An organized rhythm without a pulse tells the team what the monitor
and circulation are doing. It does not identify why.
A naloxone-focused resuscitation becomes dangerous if it narrows the
differential prematurely.
The team must still evaluate likely reversible causes. A patient with
hemorrhage needs hemorrhage control. Tension pneumothorax requires
decompression when indicated. Hyperkalemia requires appropriate
treatment. Pulmonary embolism, tamponade, hypoxia, and toxicologic
causes require their own reasoning.
Naloxone belongs inside that framework when opioid toxicity is
plausible.
Polysubstance
Overdose Complicates Everything
An opioid antagonist only antagonizes opioid effects.
It does not reverse every sedative or stimulant. It does not correct
hypoxemia, sodium-channel blockade, hemorrhage, hyperkalemia, pulmonary
embolism, or another simultaneous cause of arrest.
Failure to improve after naloxone therefore does not exclude opioid
involvement.
Likewise, a response to naloxone does not prove opioids were the only
problem.
What EMS Crews Should Do
Operationally
Start standard
resuscitation immediately
Do not delay compressions, ventilation, rhythm analysis,
defibrillation when indicated, or other established arrest care.
Establish effective
ventilation
A hypoxic mechanism makes ventilation particularly important. Airway
positioning, mask seal, appropriate rate, visible chest rise, oxygen
delivery, suction readiness, and escalation of airway strategy
matter.
Gather history in parallel
One crew member can ask witnesses about preceding respiratory
pattern, drug exposure, prior naloxone, co-ingestants, medical history,
and collapse timing while resuscitation continues.
Integrate
naloxone without disrupting priorities
If opioid-associated arrest is suspected and protocol allows
naloxone, medication administration should occur as a parallel task.
Do not wait for a naloxone
response
Continue the arrest algorithm and reversible-cause assessment.
Provide full post-ROSC care
ROSC after suspected opioid-associated arrest still requires
oxygenation, ventilation, hemodynamic management, ECG assessment,
neurologic evaluation, and appropriate destination planning.
What EMS Systems Should
Measure
Quality review should go beyond “naloxone given.”
Useful variables include presenting rhythm, suspected etiology,
witness status, bystander CPR, naloxone route and timing, ventilation
method, airway interventions, ETCO2 when available, CPR quality, ROSC,
rearrest, survival to admission, survival to discharge, neurologic
outcome when available, and whether opioid involvement was later
confirmed or remained suspected.
The purpose should be system learning rather than punitive
review.
Training Scenario
Dispatch
Adult unconscious, possible overdose.
Arrival
A simulated 34-year-old patient is found on a bedroom floor. A friend
reports that the patient became unusually sleepy and was “breathing
weird” before becoming unresponsive.
The patient is apneic and pulseless. Initial rhythm is organized at
approximately 48/min with no pulse.
The friend reports possible fentanyl exposure but is unsure whether
other substances were involved.
Expected actions
The team should recognize arrest, begin high-quality CPR, establish
BVM ventilation with oxygen, confirm PEA, establish access according to
protocol, provide standard arrest medications, assess reversible causes,
recognize opioid toxicity as plausible, and administer naloxone if
permitted without interrupting established resuscitation.
The team should not wait for a naloxone response before continuing
the arrest algorithm.
Instructor inject
ROSC occurs, but the patient remains apneic.
Ask the team what has changed.
The correct answer is not “the overdose is fixed.” Circulation has
returned, but airway and ventilatory support, reassessment, post-arrest
management, and continued evaluation for co-ingestants remain
necessary.
Debrief
Ask:
- Did naloxone distract from CPR?
- Was ventilation effective before medication administration?
- What evidence suggested opioid involvement?
- What other causes of PEA were considered?
- Would naloxone have been used without any overdose clues?
- How would management differ if the patient had a pulse on
arrival? - What does the 2026 study actually prove?
Common Misconceptions
“Naloxone
does not work once cardiac arrest starts.”
That is too absolute. Evidence is uncertain rather than definitively
negative. AHA guidance allows naloxone as a reasonable consideration in
suspected opioid-associated cardiac arrest when standard resuscitation
is not disrupted.
“The new
study proves naloxone improves PEA survival.”
No. It demonstrates an observational association.
“PEA means opioid overdose.”
No. PEA has many causes.
“Naloxone can replace
ventilation.”
No. Ventilation is central to opioid respiratory arrest and
appropriate compression-ventilation CPR.
“No
response to naloxone means opioids were not involved.”
No. Arrest physiology, route, timing, and polysubstance exposure
complicate response.
“Naloxone is
safe, so every arrest should get it.”
Medication safety is not the only consideration. Task saturation and
opportunity cost matter. An intervention should be clinically justified
and should not interfere with interventions of established benefit.
Does This Change Practice?
What the study found
In more than 40,000 EMS-attended OHCA cases, naloxone was associated
with higher survival to hospital discharge among propensity-matched
patients presenting in PEA. Prehospital ROSC was not significantly
different in that subgroup, and corresponding benefit was not identified
in shockable rhythms or asystole.
What it does not prove
It does not establish causality, justify naloxone for every PEA
arrest, define an optimal dose or route, or supersede standard
resuscitation.
What current guidance says
The 2025 AHA Guidelines say opioid antagonist administration may be
reasonable in suspected opioid-associated cardiac arrest if it does not
interfere with standard compression-ventilation resuscitation.
What this means for training
EMS education should move away from the binary claim that naloxone
either “works” or “does not work” during arrest.
A better model is:
Recognize the likely mechanism. Prioritize established
resuscitation. Integrate naloxone when opioid-associated arrest is
plausible and it can be done without compromising CPR, ventilation,
rhythm management, or reversible-cause treatment.
Practice-change conclusion
No immediate protocol change should be made solely because of
this observational study.
The paper strengthens the rationale for prospective research and
supports thoughtful application of existing AHA guidance.
The greatest opportunity remains earlier: recognize opioid-induced
respiratory failure, ventilate effectively, administer opioid reversal
when appropriate, and prevent progression to cardiac arrest.
How This
Study Fits the Earlier Naloxone Literature
The 2026 PEA paper did not appear in an evidence vacuum.
Before its publication, the literature on intra-arrest naloxone was
already inconsistent. That inconsistency was examined directly in a 2025
systematic review commissioned through the International Liaison
Committee on Resuscitation Advanced Life Support Task Force.
The review searched major databases through September 2024 for
randomized or observational studies evaluating opioid-specific advanced
life-support interventions during cardiac arrest. Investigators screened
more than one thousand records and ultimately included six observational
studies. Five evaluated naloxone and one evaluated bicarbonate.
No randomized controlled trial of naloxone during opioid-associated
cardiac arrest was identified.
That point deserves emphasis because it sets the ceiling on what
could be concluded.
Among the naloxone studies, some reported an association with
improved outcomes and others did not. The populations were
heterogeneous. Some studies included undifferentiated cardiac arrests.
Others used nonshockable rhythm or a “drug-related” classification as a
proxy for opioid-associated arrest. Importantly, the systematic review
noted that none of the included studies exclusively examined cardiac
arrests definitively caused by opioid toxicity.
The reviewers judged the evidence to have serious risk of bias and
indirectness, with very low certainty.
Their conclusion was appropriately cautious: the available evidence
did not demonstrate a benefit from an opioid-specific advanced
life-support intervention during cardiac arrest, and a clinical trial
was warranted.
The 2026 Niederberger study changes the evidence landscape by adding
a large rhythm-stratified national cohort. It does not erase the
limitations identified in the systematic review.
Instead, the two pieces of evidence should be read together.
The systematic review tells us the historical evidence base was
heterogeneous, observational, and low certainty.
The new study tells us that when a very large dataset is stratified
by presenting rhythm, a survival association emerges in PEA that was not
apparent in shockable rhythms or asystole.
That is exactly the kind of finding that can generate a better
prospective research question.
It is not the same thing as answering that question.
Why rhythm stratification
matters
Combining every cardiac arrest into one group can hide clinically
meaningful subgroups.
A ventricular-fibrillation arrest from acute coronary occlusion is
physiologically different from a hypoxic PEA arrest following prolonged
respiratory depression.
If naloxone has any intra-arrest benefit, there is little reason to
assume the effect would be distributed equally across every etiology and
rhythm.
Stratification therefore makes sense.
But rhythm is still an imperfect surrogate for etiology.
A PEA subgroup contains many patients whose arrests have nothing to
do with opioids. A shockable subgroup may still include patients with
drug exposure. An asystole subgroup may contain opioid-associated
arrests that have simply progressed further before EMS arrival.
Rhythm can enrich a population for a mechanism without proving the
mechanism.
That distinction is one of the most important lessons for clinicians
reading subgroup research.
The Physiology
Behind the Clinical Question
To understand why naloxone during cardiac arrest remains
controversial, it helps to separate three physiologic problems that are
often compressed into the single word “overdose.”
Problem 1: opioid receptor
effect
Mu-opioid receptor activation suppresses respiratory drive and can
impair airway protection.
Naloxone directly addresses this component.
Problem 2: respiratory
failure
Once ventilation becomes inadequate, hypoxemia and hypercapnia
develop.
Naloxone may eventually restore spontaneous respiratory effort if
opioid effect is the primary cause, but assisted ventilation directly
addresses the gas-exchange emergency while that reversal is
occurring.
Problem 3: cardiac arrest
Once circulation stops, the patient has a perfusion problem in
addition to the respiratory and toxicologic problems.
Chest compressions are now needed to create blood flow. The
effectiveness of every intravenously or intraosseously administered
medication is influenced by the limited circulation generated during
CPR.
The medication may antagonize opioid receptors, but it does not
mechanically create coronary perfusion pressure.
It does not substitute for chest compressions.
It does not ventilate the lungs.
It does not defibrillate ventricular fibrillation.
This is why the clinical importance of naloxone is strongest before
arrest and much less certain after arrest.
The
Prevention Opportunity Is Larger Than the Intra-Arrest Question
The most important implication of opioid resuscitation may not be
whether naloxone improves survival after PEA develops.
It may be how often PEA could have been prevented.
Opioid poisoning frequently offers a period during which severe
respiratory depression precedes complete cardiovascular collapse.
That creates a potential rescue window.
A bystander who recognizes abnormal breathing, activates EMS,
provides ventilatory support when trained and appropriate, and
administers naloxone may interrupt the pathway before pulselessness
occurs.
EMS clinicians arriving during respiratory arrest have an even
clearer opportunity.
The patient with a pulse can circulate naloxone far more effectively
than a patient dependent on CPR-generated blood flow.
Effective BVM ventilation can begin immediately.
Airway obstruction, aspiration, pulmonary edema, co-ingestion,
hypoglycemia, trauma, and other problems can be assessed.
This is one reason public naloxone availability and overdose
recognition remain so important even while researchers debate
intra-arrest efficacy.
The best PEA arrest may be the one that never develops.
Ventilation Quality
Deserves More Attention
Opioid-associated resuscitation should also force EMS educators to
examine how well crews actually ventilate patients.
Saying “bag the patient” is not enough.
Effective BVM ventilation is a technical skill.
Mask seal matters.
Airway position matters.
Adjunct selection matters.
Rate matters.
Volume matters.
Airway obstruction matters.
Gastric insufflation matters.
Suction readiness matters.
Two-person technique can matter.
The patient’s body habitus, facial anatomy, dentition, secretions,
pulmonary pathology, and aspiration risk all influence success.
A crew can document “BVM ventilation” while delivering poor
ventilation.
That matters in any arrest, but it is particularly relevant when
respiratory failure is central to the presumed mechanism.
Training should therefore connect opioid resuscitation with actual
airway-performance assessment rather than treating naloxone as the
entire lesson.
The
Danger of the Medication-Centered Overdose Scenario
Many overdose simulations are built around a medication endpoint.
The learner recognizes pinpoint pupils, says “opioid overdose,”
administers naloxone, and the manikin “wakes up.”
That is simple to teach.
It can also create bad habits.
Real opioid emergencies may not present with textbook pupils.
The patient may not wake up immediately.
The patient may have vomited.
The patient may be profoundly hypoxemic.
The patient may have aspirated.
The patient may have co-ingested benzodiazepines, alcohol,
stimulants, or other substances.
The patient may already be in cardiac arrest.
A better simulation evaluates whether learners identify and manage
the physiology.
Can they recognize inadequate breathing?
Can they open and maintain the airway?
Can they ventilate effectively?
Can they distinguish respiratory arrest with a pulse from cardiac
arrest?
Can they begin CPR without wasting time searching for naloxone?
Can they integrate naloxone as a parallel task?
Can they reassess after ROSC?
That is a stronger educational model because it remains useful even
when the suspected diagnosis is wrong.
Route and Timing During
Cardiac Arrest
The 2026 study does not establish an optimal naloxone route during
arrest.
That limitation is operationally important.
Intranasal naloxone is highly accessible and has transformed
community overdose response. But medication delivered through the nasal
mucosa depends on absorption before reaching systemic circulation.
During cardiac arrest, peripheral perfusion is profoundly
abnormal.
Intravenous or intraosseous administration places medication directly
into the vascular compartment, but systemic distribution still depends
on CPR-generated circulation.
This creates a research question rather than a simple answer.
If naloxone is going to have an intra-arrest effect, route and timing
may matter substantially.
A dose administered immediately after a witnessed respiratory arrest
progresses to PEA may not be physiologically equivalent to a dose
administered late in prolonged resuscitation after extended hypoxia.
Similarly, a patient who received intranasal naloxone immediately
before becoming pulseless may differ from one first receiving medication
after vascular access is established during ALS care.
These are precisely the details that retrospective datasets may not
capture with enough granularity to determine an optimal strategy.
EMS protocols should therefore not invent a new route hierarchy from
this study.
Why
Survival Without a Significant ROSC Signal Is Interesting
The matched PEA analysis reported higher survival to hospital
discharge with naloxone but did not show a statistically significant
difference in prehospital ROSC.
That pattern deserves attention.
ROSC is usually an intermediate step on the pathway to survival.
If a treatment directly improves resuscitation physiology, clinicians
might expect to see some corresponding effect on ROSC.
There are several possible explanations for the observed pattern.
Chance is one possibility.
Residual confounding is another.
Differences after ROSC or in hospital care may also matter.
Measurement and documentation may differ.
The naloxone-exposed population may possess characteristics
associated with better ultimate survival that were not completely
balanced by matching.
There may also be a real effect that the study was not structured to
fully explain.
The correct response is not to force the data into a mechanism.
It is to identify the inconsistency and recognize it as another
reason a randomized trial is needed.
Neurologic Outcome
Matters, Not Just Survival
Survival to discharge is important.
For cardiac-arrest research, neurologic outcome is also critical.
A therapy that increases survival but produces no improvement in
meaningful neurologic recovery would require a different interpretation
from one that improves both.
Opioid-associated arrests may involve prolonged hypoxemia before
pulselessness is recognized.
That pre-arrest hypoxic interval can influence neurologic injury even
when circulation is eventually restored.
Future research should therefore evaluate favorable neurologic
survival, not simply ROSC or discharge status.
EMS systems considering local research or QI projects should keep
this endpoint in mind.
Bystander
Naloxone and EMS Naloxone Are Different Questions
Another source of confusion is the tendency to treat all naloxone
administration as the same intervention.
Community naloxone programs primarily target overdose before or
around the transition to respiratory arrest.
That public-health intervention has a different evidence question
from intra-arrest naloxone administered by EMS.
For the bystander, rapid opioid reversal may prevent arrest.
For the EMS clinician treating established PEA, the question is
whether adding an antagonist during standard resuscitation improves
outcome.
Those should not be conflated.
A lack of definitive evidence for intra-arrest naloxone would not
undermine community naloxone distribution.
Likewise, the effectiveness of naloxone in reversing respiratory
depression does not automatically prove benefit once cardiac arrest is
established.
A Better EMS Decision
Framework
A practical framework can be organized around circulation.
Patient is
breathing adequately and perfusing
Assess, monitor, investigate exposure, and treat according to the
clinical situation and protocol.
Patient
has respiratory depression but a definite pulse
Support the airway.
Provide ventilation when breathing is inadequate.
Administer naloxone when opioid toxicity is suspected.
Reassess frequently.
Prepare for recurrence because the duration of opioid effect may
exceed that of naloxone.
Patient
is in respiratory arrest with a definite pulse
Ventilation becomes urgent.
Administer naloxone.
Do not wait for spontaneous breathing to return before supporting gas
exchange.
Patient is pulseless
Begin standard cardiac-arrest resuscitation.
Provide appropriate compression-ventilation CPR.
Analyze rhythm.
Defibrillate when indicated.
Treat reversible causes.
When opioid-associated arrest is suspected, naloxone may be
incorporated if doing so does not interfere with established
resuscitation.
This framework prevents a medication from replacing physiology-based
care.
What
Medical Directors and Protocol Committees Should Ask
The new study may prompt protocol review.
A good review should ask several questions before changing
language.
Does the current protocol prohibit naloxone after arrest even when
opioid toxicity is strongly suspected?
Does it already permit administration without prioritizing it over
standard ALS?
Does protocol wording inadvertently encourage crews to stop
established care while waiting for a response?
Does the system have enough personnel for medication preparation to
occur in parallel?
What routes are available?
What does the local evidence review conclude about certainty?
How will the change be taught?
How will compliance and outcomes be evaluated?
Will the protocol distinguish respiratory arrest from cardiac arrest
clearly?
A protocol change should solve an identified problem.
The existence of a new observational association is not, by itself,
evidence that every system needs new medication instructions.
Documentation
Should Capture Clinical Reasoning
If naloxone is administered during arrest, documentation should help
later reviewers understand why.
Useful narrative elements include:
- evidence supporting suspected opioid exposure;
- whether the arrest was witnessed;
- the patient’s condition before pulselessness when known;
- whether bystander naloxone was administered;
- presenting rhythm;
- naloxone route, dose, and timing;
- relationship to CPR cycles and vascular access;
- ventilation strategy;
- ETCO2 trends when available;
- ROSC timing;
- and other suspected reversible causes.
This information improves QI and makes future retrospective research
more meaningful.
Instructor
Discussion: How to Teach Uncertain Evidence
Educators have a responsibility to distinguish evidence certainty
from enthusiasm.
A new study with a compelling headline can easily become an
oversimplified slide:
“Naloxone improves survival in PEA.”
That would go beyond the data.
A stronger instructor sequence is:
First: explain the clinical question.
Second: describe the study design.
Third: present the result.
Fourth: identify limitations.
Fifth: compare the result with the systematic review
and current guideline.
Sixth: explain what should and should not change at
the bedside.
Learners should leave knowing both the finding and its
uncertainty.
That is evidence literacy.
Research Questions
That Should Come Next
The next generation of research should attempt to answer questions
the current study cannot.
A prospective trial could examine suspected opioid-associated
nonshockable OHCA and compare standard resuscitation with standard
resuscitation plus protocolized naloxone.
Important design questions would include:
- how opioid-associated arrest is defined;
- whether PEA and asystole are analyzed separately;
- naloxone route;
- dose;
- timing from EMS arrival and from vascular access;
- prior bystander naloxone;
- CPR quality;
- ventilation strategy;
- ETCO2;
- ROSC;
- survival to discharge;
- favorable neurologic outcome;
- and confirmation of opioid exposure when feasible.
The challenge is substantial because opioid-associated arrest is
difficult to identify prospectively with certainty.
But without better trials, clinicians will continue trying to infer
causality from treatment decisions made in uncontrolled real-world
settings.
Final Perspective
The question “Does naloxone work in cardiac arrest?” sounds
simple.
The evidence is not.
Naloxone unquestionably matters in opioid emergencies because
opioid-induced respiratory depression is reversible, and early treatment
can prevent deterioration.
Once cardiac arrest occurs, standard resuscitation becomes
dominant.
The 2026 PEA study is important because it identifies a large,
rhythm-specific survival association that deserves further
investigation.
The 2025 systematic review is equally important because it reminds us
that the broader evidence remains heterogeneous and very low
certainty.
The 2025 AHA Guidelines provide the practical bridge between those
facts: naloxone may be reasonable during suspected opioid-associated
cardiac arrest, but it must not interfere with standard
compression-ventilation resuscitation.
That is a balanced position.
It acknowledges biologic plausibility.
It acknowledges uncertainty.
And it protects the interventions with the strongest established role
in cardiac arrest.
For EMS education, the lesson is bigger than a medication.
Recognize respiratory failure early.
Ventilate well.
Treat opioid toxicity when appropriate.
Recognize when the patient has crossed into cardiac arrest.
Run the arrest well.
Consider naloxone when the mechanism fits.
And never allow a promising adjunct to become a distraction from
foundational resuscitation.
FAQ
Should
paramedics give naloxone to every PEA arrest?
No. Evidence does not support routine naloxone for every PEA
arrest.
Is
naloxone recommended for opioid respiratory arrest with a pulse?
Yes. Current AHA guidance recommends opioid antagonist administration
for suspected opioid-associated respiratory arrest with a definite
pulse, together with airway and ventilatory support.
Is naloxone
recommended during cardiac arrest?
AHA states it may be reasonable when opioid overdose is suspected,
provided it does not interfere with standard resuscitation.
Why is PEA relevant?
Severe opioid toxicity can progress through respiratory failure and
hypoxia to bradycardia and PEA, but PEA is not specific to opioids.
Does
naloxone replace epinephrine or other standard arrest care?
No. It is an adjunct when appropriate.
Did the 2026 study
show naloxone causes ROSC?
No. In the matched PEA analysis, survival to discharge was associated
with naloxone while prehospital ROSC was not significantly
different.
Key Takeaways
- Naloxone has a clear role in suspected opioid-associated respiratory
arrest with a pulse. - Once cardiac arrest occurs, standard resuscitation is the
priority. - AHA says naloxone may be reasonable during suspected
opioid-associated arrest if it does not interfere with
compression-ventilation CPR. - The 2026 study analyzed 40,333 OHCA cases.
- Naloxone was associated with higher survival to discharge in matched
PEA cases. - The study cannot establish causality.
- PEA may be biologically relevant but is not a diagnosis of opioid
poisoning. - Naloxone is an adjunct, not a replacement for CPR, ventilation,
rhythm management, or reversible-cause treatment. - EMS systems should examine workflow and outcomes, not merely whether
naloxone was administered. - Preventing opioid respiratory arrest from progressing to cardiac
arrest remains a major opportunity.
Internal Linking Suggestions
Link this guide to the Life Saving Education BLS, ACLS, CPR/AED, EMS
education, airway-management, and cardiac-arrest education pages. Use
descriptive anchor text.
CTA
Build
Resuscitation Skills Around the Patient, Not Just the Algorithm
Life Saving Education provides evidence-informed CPR, BLS, ACLS, EMS,
and emergency-response education connecting current guidance with
real-world decision-making.
Explore upcoming training or contact Life Saving Education
about customized EMS and resuscitation education.
References
- Niederberger SM, Wang RC, Rodriguez RM, et al. Naloxone
administration associated with improved survival in PEA out-of-hospital
cardiac arrests. Resuscitation. 2026;225:111139.
doi:10.1016/j.resuscitation.2026.111139. - Cao D, Arens AM, Chow SL, et al. Part 10: Adult and Pediatric
Special Circumstances of Resuscitation: 2025 American Heart Association
Guidelines for Cardiopulmonary Resuscitation and Emergency
Cardiovascular Care. Circulation.
2025;152(16_suppl_2):S578-S672. doi:10.1161/CIR.0000000000001380. - American Heart Association. 2025 Guidelines for CPR and ECC, Part
10: Adult and Pediatric Special Circumstances of Resuscitation. - Dezfulian C, et al. Opioid-associated out-of-hospital cardiac
arrest: distinctive clinical features and implications for health care
and public responses. Circulation. 2021. - Grunau B, et al. Opioid-associated cardiac arrest: systematic review
of intra-arrest naloxone and other opioid-specific advanced life-support
therapies. Resuscitation Plus. 2025.
Educational Scope Note
This article is educational and is not a patient-specific treatment
protocol. EMS clinicians should follow applicable protocols, medical
direction, scope of practice, current resuscitation guidance, and
medication policies. Observational evidence should not be interpreted as
establishing a new universal standard of care.
